Cargando…

Neuromuscular Diseases Care in the Era of COVID-19

The COVID-19 pandemic has pushed health systems to their limit and forced readjustment of standards of care for different pathologies. Management of neuromuscular diseases becomes a challenge since most of them are chronic, disabling, progressive, and/or require immunosuppressive drugs. There are th...

Descripción completa

Detalles Bibliográficos
Autores principales: Bertran Recasens, Bernat, Rubio, Miguel Angel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7732578/
https://www.ncbi.nlm.nih.gov/pubmed/33329336
http://dx.doi.org/10.3389/fneur.2020.588929
_version_ 1783622123982422016
author Bertran Recasens, Bernat
Rubio, Miguel Angel
author_facet Bertran Recasens, Bernat
Rubio, Miguel Angel
author_sort Bertran Recasens, Bernat
collection PubMed
description The COVID-19 pandemic has pushed health systems to their limit and forced readjustment of standards of care for different pathologies. Management of neuromuscular diseases becomes a challenge since most of them are chronic, disabling, progressive, and/or require immunosuppressive drugs. There are three main aspects of COVID-19 that affect neuromuscular diseases care. The first one relates to how SARS-CoV2 directly affects different neuromuscular pathologies. Respiratory weakness, as seen in myasthenia gravis, amyotrophic lateral sclerosis, and myopathies, and the use of immunomodulatory drugs (Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy) make this group of patients potentially more vulnerable. Secondly, safety measures also affect proper care, limiting care continuity, and physical rehabilitation (one of the essential aspects of myopathies treatment). Telemedicine can partially solve the problem allowing for a continuum of close care, avoiding unnecessary visits, and even guaranteeing the attention of professionals from tertiary care centers. However, one of the crucial steps in neuromuscular diseases is diagnosis, and in most scenarios, more than one face-to-face visit is needed. Lastly, the global COVID-19 situation will also have an economic impact on patients and their families. This situation is of particular concern given that neuromuscular diseases already present difficulties due to the scarcity of resources in terms of public healthcare and research.
format Online
Article
Text
id pubmed-7732578
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-77325782020-12-15 Neuromuscular Diseases Care in the Era of COVID-19 Bertran Recasens, Bernat Rubio, Miguel Angel Front Neurol Neurology The COVID-19 pandemic has pushed health systems to their limit and forced readjustment of standards of care for different pathologies. Management of neuromuscular diseases becomes a challenge since most of them are chronic, disabling, progressive, and/or require immunosuppressive drugs. There are three main aspects of COVID-19 that affect neuromuscular diseases care. The first one relates to how SARS-CoV2 directly affects different neuromuscular pathologies. Respiratory weakness, as seen in myasthenia gravis, amyotrophic lateral sclerosis, and myopathies, and the use of immunomodulatory drugs (Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy) make this group of patients potentially more vulnerable. Secondly, safety measures also affect proper care, limiting care continuity, and physical rehabilitation (one of the essential aspects of myopathies treatment). Telemedicine can partially solve the problem allowing for a continuum of close care, avoiding unnecessary visits, and even guaranteeing the attention of professionals from tertiary care centers. However, one of the crucial steps in neuromuscular diseases is diagnosis, and in most scenarios, more than one face-to-face visit is needed. Lastly, the global COVID-19 situation will also have an economic impact on patients and their families. This situation is of particular concern given that neuromuscular diseases already present difficulties due to the scarcity of resources in terms of public healthcare and research. Frontiers Media S.A. 2020-11-26 /pmc/articles/PMC7732578/ /pubmed/33329336 http://dx.doi.org/10.3389/fneur.2020.588929 Text en Copyright © 2020 Bertran Recasens and Rubio. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Bertran Recasens, Bernat
Rubio, Miguel Angel
Neuromuscular Diseases Care in the Era of COVID-19
title Neuromuscular Diseases Care in the Era of COVID-19
title_full Neuromuscular Diseases Care in the Era of COVID-19
title_fullStr Neuromuscular Diseases Care in the Era of COVID-19
title_full_unstemmed Neuromuscular Diseases Care in the Era of COVID-19
title_short Neuromuscular Diseases Care in the Era of COVID-19
title_sort neuromuscular diseases care in the era of covid-19
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7732578/
https://www.ncbi.nlm.nih.gov/pubmed/33329336
http://dx.doi.org/10.3389/fneur.2020.588929
work_keys_str_mv AT bertranrecasensbernat neuromusculardiseasescareintheeraofcovid19
AT rubiomiguelangel neuromusculardiseasescareintheeraofcovid19